{"id":990037,"date":"2026-08-05T07:19:52","date_gmt":"2026-08-05T11:19:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-05T07:19:52","modified_gmt":"2026-08-05T11:19:52","slug":"biocryst-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-reports-second-quarter-2026-financial-results\/","title":{"rendered":"BioCryst Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n
\n \u2014 Total net revenue of $218.3 million and ORLADEYO<\/em>
\n <\/strong>
\n \u00ae<\/sup>
\n
\n net revenue of $158.2 million \u2014<\/em>
\n <\/strong>\n <\/p>\n

\n
\n \u2014 Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million \u2014<\/em>
\n <\/strong>\n <\/p>\n

\n
\n \u2014 Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million \u2014<\/em>
\n <\/strong>\n <\/p>\n

\n
\n \u2014 Began shipping ORLADEYO oral pellets to pediatric patients on August 3 \u2014<\/em>
\n <\/strong>\n <\/p>\n

\n
\n \u2014 Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart \u2014<\/em>
\n <\/strong>\n <\/p>\n

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) — \u00a0BioCryst Pharmaceuticals, Inc.<\/a> (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.<\/p>\n

\u201cWe were pleased to deliver strong revenue growth and positive free cash flow again in the second quarter, reflecting our continued focus on expanding the reach of ORLADEYO while advancing our prioritized pipeline programs,\u201d said Charlie Gayer, President and Chief Executive Officer of BioCryst. \u201cWe are especially excited to have begun shipments of the ORLADEYO oral pellet formulation \u2013 an important milestone for children living with hereditary angioedema \u2013 and we are fully committed to making the launch a success.<\/p>\n

\u201cAcross our pipeline, we completed enrollment in our pivotal navenibart trial and continued to advance BCX17725 toward early clinical data in patients by year-end. As we announced in June, we have rationalized our internal R&D efforts to better align our cost structure with our shift toward external innovation to build our pipeline. These changes will allow us to more efficiently allocate capital toward compelling assets where we have differentiated clinical and commercial expertise.<\/p>\n

\u201cBuilding on this momentum, we remain focused on cost discipline while directing our capital and energy toward opportunities where we can have the greatest impact. This positions BioCryst exceptionally well to continue delivering growth, strong profitability, and lasting value for patients and their families as well as our shareholders.\u201d<\/p>\n

\n
\n Business & Corporate Updates<\/em>
\n <\/strong>\n <\/p>\n